ID
12738
Description
Phase I Study of Adoptive Immunotherapy With Enriched and Expanded Autologous Natural Killer (NK) Cells for Patients With Ph+ Acute Lymphoblastic Leukemia (ALL); ODM derived from: https://clinicaltrials.gov/show/NCT02185781
Link
https://clinicaltrials.gov/show/NCT02185781
Keywords
Versions (1)
- 12/17/15 12/17/15 -
Uploaded on
December 17, 2015
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Acute Lymphoblastic Leukemia NCT02185781
Eligibility Acute Lymphoblastic Leukemia NCT02185781
- StudyEvent: Eligibility
Description
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Description
concomitant therapy
Data type
boolean
Alias
- UMLS CUI [1]
- C1707479
Description
contraindication
Data type
boolean
Alias
- UMLS CUI [1]
- C1301624
Description
infection
Data type
boolean
Alias
- UMLS CUI [1]
- C0009450
Description
autoimmune symptoms
Data type
boolean
Alias
- UMLS CUI [1]
- C0004364
Description
pregnant or breastfeeding
Data type
boolean
Alias
- UMLS CUI [1]
- C0549206
- UMLS CUI [2]
- C0006147
Description
Study subject participation status
Data type
boolean
Alias
- UMLS CUI [1]
- C2348568
Description
any physical or psychological impediment in a patient that could lead the investigator to suspect his/her poor compliance to the protocol.
Data type
boolean
Alias
- UMLS CUI [1]
- C1321605
- UMLS CUI [2]
- C0439801
- UMLS CUI [3]
- C0009488
Similar models
Eligibility Acute Lymphoblastic Leukemia NCT02185781
- StudyEvent: Eligibility
C0232741 (UMLS CUI [2])
C0232804 (UMLS CUI [3])
C0018724 (UMLS CUI [1,2])
C0006147 (UMLS CUI [2])
C0439801 (UMLS CUI [2])
C0009488 (UMLS CUI [3])